TIGIT distinguishes itself by its broad expression across a spectrum of immune cells integral to anti-tumor immunity, notably T cells, natural killer (NK) cells, and regulatory T cells (Tregs). Mechanistically, TIGIT exerts a multifaceted immunosuppressive influence primarily through its competitive engagement with ligands CD155 and CD112. This competitive binding interrupts the activating signals mediated by CD226, a co-stimulatory receptor imperative for robust T and NK cell cytotoxic activity. The result is a suppressive tumor microenvironment that favors tumor immune evasion and sustains hypoxia-linked immunosuppression, complicating therapeutic intervention.

Intriguingly, TIGIT’s role transcends mere ligand competition. It has been observed to interfere with the cis-dimerization of CD226, further dampening cytotoxic signaling pathways. Moreover, TIGIT directly binds CD155 expressed on dendritic cells (DCs), hindering their maturation and function—an effect compounded by TIGIT-mediated induction of the anti-inflammatory cytokine interleukin-10 (IL-10). This cytokine milieu skews the immune response away from effective tumor eradication, simultaneously fostering Treg maturation and the elevated expression of the transcription factor Foxp3, a master regulator of immunosuppressive Tregs.

The clinical relevance of TIGIT expression has been substantiated across various malignancies, including breast, colorectal, and pancreatic cancers, where elevated TIGIT levels correlate with adverse patient outcomes. Comprehensive analyses of The Cancer Genome Atlas (TCGA) data reveal that heightened TIGIT expression in breast cancer tissues significantly associates with diminished overall survival rates and reduced progression-free intervals. These findings underscore TIGIT’s potential as a prognostic biomarker, with a sensitivity that, in some cases, surpasses that of programmed death-1 (PD-1), another well-characterized immune checkpoint.

Therapeutically, targeting TIGIT presents both challenges and opportunities. Monotherapy with TIGIT inhibitors has exhibited limited efficacy in clinical settings, prompting exploration of combinatorial strategies. Notably, dual blockade of TIGIT and PD-1 pathways has demonstrated profound immunologic synergy. The phase II CITYSCAPE trial exemplifies this approach, where the anti-TIGIT antibody tiragolumab, in conjugation with the anti-PD-1 agent atezolizumab, markedly improved objective response rates and progression-free survival in non-small cell lung cancer (NSCLC) patients compared to PD-1 inhibition alone. This synergy is attributed to TIGIT blockade’s capacity to reverse T-cell exhaustion and mitigate NK cell depletion, effectively overcoming mechanisms of PD-1 resistance.

Several TIGIT inhibitors are currently advancing through late-phase clinical trials, with agents such as vibostolimab, tiragolumab, and ociperlimab demonstrating promising profiles in solid tumors. Concurrently, innovative platforms are developing dual-target antibodies, exemplified by candonilimab, which concurrently targets TIGIT and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), aiming to amplify immunostimulatory effects while curtailing toxicity. These agents represent a new frontier in precision immunotherapy, designed to strategically dismantle tumor-induced immune suppression.

Future research directives are poised to refine this therapeutic landscape by identifying robust biomarkers predictive of response to TIGIT-targeted treatment, optimizing dosing regimens, and exploring combinatorial frameworks with metabolic or epigenetic modulators. The integration of these approaches promises to enhance the durability and breadth of clinical responses, potentially transforming the current paradigms of cancer management.

Fundamentally, TIGIT-centered immunotherapy embodies a translational strategy with the scope to transcend the heterogeneity and complexity of tumor immunobiology. By intricately modulating multiple axes of immune regulation, TIGIT inhibition offers a strategic lever to recalibrate antitumor immunity, thereby surmounting the resistance that plagues existing immunotherapeutic regimens. This positions TIGIT not merely as a novel checkpoint inhibitor but as a pivotal fulcrum for the next generation of cancer immunotherapy.

The evolving body of evidence positions TIGIT as a biomarker of paramount importance, one that may soon redefine patient stratification and therapeutic decision-making in oncology. Its superior specificity in delineating exhausted CD8+ T-cell phenotypes compared to PD-1 enhances its utility beyond a therapeutic target, extending into realms of prognostication and personalized medicine. This nuanced understanding underscores the imperative for comprehensive translational research to expedite TIGIT’s clinical application.

In summary, the burgeoning research landscape illuminates TIGIT as a vital node in the tumor-immune interface with multifarious implications for cancer progression and immune escape. Through direct and indirect mechanisms—ranging from ligand competition and inhibitory signaling to modulation of dendritic cell functionality and regulatory T cell activity—TIGIT orchestrates a profound immunosuppressive milieu that tumors exploit for survival and growth. Its targeted inhibition holds transformative potential, promising to reshape therapeutic trajectories across an array of malignancies.

By harnessing the intricate biology of TIGIT and integrating it into multi-modal treatment regimens, the scientific and clinical communities stand on the cusp of a paradigm shift. This convergence of mechanistic insight and therapeutic innovation charts a promising course towards achieving durable, robust antitumor immunity, ultimately propelling the field closer to the aspirational goal of long-term cancer remission.

Subject of Research: Not applicable
Article Title: Role of TIGIT in tumor progression and immune evasion
News Publication Date: 30-Mar-2026
Web References: http://dx.doi.org/10.1097/JP9.0000000000000245
References: DOI: 10.1097/JP9.0000000000000245
Image Credits: Dr. Lei Wang and Dr. Jianwei Xu from Qilu Hospital of Shandong University, China
Keywords: TIGIT, immune checkpoint, tumor microenvironment, T cells, NK cells, regulatory T cells, cancer immunotherapy, PD-1, CD155, dendritic cells, T-cell exhaustion, immunosuppression

Gastric cancer remains one of the deadliest malignancies worldwide, with metastasis being the primary cause of treatment failure and mortality. Despite substantial progress in early detection and surgical techniques, the prognosis for advanced gastric cancer continues to be dismal. The complexity of metastatic dissemination involves numerous molecular players that orchestrate cell migration, invasion, and colonization of distant organs. Among these, cell–cell adhesion molecules like occludin play a pivotal role in maintaining epithelial integrity and preventing cancer cell detachment. The degradation of such junctional proteins is thus intimately linked to the invasive capabilities of cancer cells.

The team focused on the enigmatic role of A20, also known as TNFAIP3, which historically has been characterized as a negative regulator of NF-kB signaling and an anti-inflammatory molecule. Intriguingly, emerging evidence has hinted at a dualistic function of A20 in certain cancers, but the underlying mechanisms remained obscure. By employing a sophisticated blend of molecular biology, proteomics, and in vitro functional assays, Kuo and colleagues meticulously delineated how A20 enhances the migratory phenotype of gastric cancer cells by facilitating the accelerated proteolysis of occludin.

At the molecular level, the study revealed that A20 interacts directly with occludin, tagging it for ubiquitination that flags the tight junction protein for degradation via the proteasomal pathway. This reduction in occludin disrupts the structural cohesion of epithelial borders, effectively loosening the tight junction seals that ordinarily confine epithelial cells within tissue boundaries. As a consequence, gastric cancer cells acquire enhanced motility and invasiveness, thereby increasing their metastatic potential.

One particularly notable aspect of this research was the use of live-cell imaging to visualize the dynamic disassembly of tight junctions in real time following upregulation of A20 expression. The images demonstrated a rapid turnover of occludin at the plasma membrane in gastric cancer cell lines, emphasizing the direct and acute impact of A20 on cell junction integrity. These insights provide a visual affirmation of the molecular cascade that precipitates metastasis, bridging molecular details with cellular behavior.

Another critical finding lies in the connection between A20 and the ubiquitin-proteasome system, which is implicated in numerous cellular processes including protein quality control and signal transduction. By recruiting specific E3 ubiquitin ligases, A20 orchestrates the selective degradation of occludin, revealing a previously unappreciated ubiquitination axis in gastric cancer metastasis. This axis could represent a targetable vulnerability that future drugs could exploit to stabilize tight junctions and suppress cancer dissemination.

The clinical relevance of these molecular insights was underscored by analyses of gastric cancer patient samples, which showed a strong correlation between high A20 expression levels and advanced tumor stages characterized by extensive lymph node involvement and distant metastases. Immunohistochemical staining demonstrated an inverse relationship between A20 and occludin levels in tumor tissues, affirming the translational importance of the laboratory findings. This correlation may provide a powerful prognostic biomarker model for patient stratification and personalized therapy.

Moreover, functional experiments using A20 knockdown strategies effectively reduced cancer cell migration and invasion capacities in vitro. Complementary in vivo models further substantiated that silencing A20 expression impaired metastatic colonization in mouse organs, thereby illustrating that A20 is not merely correlative but functionally indispensable to the metastatic cascade. These observations spotlight A20 as a compelling molecular target for anti-metastatic drug development.

To delve deeper, the study also explored potential upstream regulators and downstream effectors in the A20-occludin signaling pathway. It identified inflammatory stimuli and tumor microenvironment factors that upregulate A20 expression, linking chronic inflammation—a known driver of gastric carcinogenesis—with enhanced metastatic behavior. Downstream, the destabilization of multiple tight junction components synergistically contributed to epithelial-to-mesenchymal transition (EMT), further heightening invasiveness and resistance to apoptosis.

The implications of these findings extend far beyond the realm of gastric cancer. Given that tight junction integrity is vital across numerous epithelial cancers, the A20-mediated degradation pathway may represent a ubiquitous mechanism exploited by malignancies to breach tissue barriers. Further research is warranted to investigate A20’s role in other cancer types, potentially broadening the impact of this discovery across oncology.

In light of the urgent need for effective anti-metastatic therapies, the identification of A20 as a promoter of occludin degradation piques considerable interest in drug repurposing and novel inhibitor design. By targeting the protein-protein interactions or the ubiquitination machinery involved, pharmaceutical interventions could be devised to restore tight junction stability and suppress cancer spread. The study paves the way for translational research aiming to transform these molecular insights into clinical remedies.

Furthermore, the integration of multi-omics and systems biology approaches in this research exemplifies modern oncology’s shift towards holistic, mechanistic understanding of cancer progression. The combination of proteomic profiling, functional genomics, and clinical correlation validates the robustness and relevance of the findings, setting a gold standard for future cancer metastasis investigations.

In sum, the pioneering work by Kuo, Wang, and Shan elucidates a critical, previously unrecognized molecular axis by which A20 enhances the metastatic capacity of gastric cancer cells. By promoting the degradation of occludin and consequently dismantling tight junctions, A20 emerges as a central orchestrator of tumor cell migration and invasion. This revelation invites new research trajectories, therapeutic strategies, and diagnostic opportunities in combating one of the most lethal forms of cancer metastasis.

As the scientific community continues to grapple with the complexities of cancer dissemination, this study stands as a beacon of progress. It highlights how revisiting known proteins with fresh perspectives can unravel hidden facets of cancer biology, inspiring hope for better management and eventual eradication of metastatic gastric cancer.

Subject of Research: Gastric cancer metastasis and molecular mechanisms of tight junction degradation

Article Title: A20 enhances the migration and metastasis of gastric cancer cells by promoting occludin degradation

Article References: Kuo, YT., Wang, HC. & Shan, YS. A20 enhances the migration and metastasis of gastric cancer cells by promoting occludin degradation. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03082-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03082-2

Keywords: Gastric cancer, metastasis, A20, occludin, tight junctions, ubiquitination, proteasomal degradation, epithelial-to-mesenchymal transition, cancer cell migration